Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

With SYNGENE's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 0.000000
forwardPE 44.267765
debtToEquity 12.226000
earningsGrowth 0.144000
revenueGrowth 0.107000
grossMargins 0.681930
operatingMargins 0.114350
trailingEps 12.630000
forwardEps 16.850000

Syngene International Limited's low Debt-to-Equity ratio means it is not excessively leveraged, implying a reduced financial risk profile. This suggests Syngene International Limited maintains a well-balanced financial structure, with more emphasis on equity than debt, ensuring greater flexibility and long-term stability.
SYNGENE's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as SYNGENE's increasing profits and sales signal further growth in the near future.
With a forward EPS greater than its trailing EPS, SYNGENE is forecasted to be more profitable this year than last. This growth expectation reflects confidence in the company's earnings potential and suggests an improving financial trajectory for the year ahead.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

The gradual downward revision of SYNGENE's price projections signals decreasing confidence in the company's future performance. Analysts are adjusting their expectations, reflecting uncertainty about SYNGENE's growth potential.

Insider Transactions:

Insider Transactions for SYNGENE
Insider Transactions for SYNGENE


There were 17 SYNGENE stock sales, with market price at 856.0235236672794.During the period under review, no sell transactions were recorded.An increase in buying activity relative to selling at Syngene International Limited's current price might suggest a favorable sentiment among investors. This trend could be interpreted as a sign that the stock has a positive outlook in the near term.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


Analysts have shown a buy bias for SYNGENE, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to SYNGENE, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.